Clinical trials: Epidermal Necrolysis
Stevens-Johnson Syndrome Toxic Epidermal Necrolysis Spectrum
Nutritional and Metabolic Management of Toxidermia Patients Requiring Intensive Care (TEN Metabolism)
Retrospective observational cohort study including all patients admitted for toxidermia (Lyell syndrome, Stevens-Johnson Syndrome (SJS), or other extensive skin destruction) to the Burn unit of the adult ICU of the Lausanne burn…
- Trial name
- TEN metabolism (NCT05320653)
- Testing
- Medical nutrition
- Volunteers
- 35 people
- Sponsor
- Centre Hospitalier Universitaire Vaudois
Toxic Epidermal Necrolysis, Immunotherapy
New Therapeutic Target for Toxic Epidermal Necrolysis (TEN) Using Anti-CD38+ Monoclonal Antibodies.
Toxic Epidermal Necrolysis (TEN) are rare diseases that are dermatologic emergencies characterized by widespread epidermal necrosis and sloughing of skin. A hundred patients are affected each year in France.
- Conditions
- Toxic Epidermal Necrolysis, Immunotherapy, Cutaneous Adverse Drug Reactions (CADR)
- Trial name
- NET-CD38 (NCT07110662)
- Testing
- DARATUMUMAB (DARZALEX®)
- Where
- France
- Volunteers
- 9 people
- Sponsor
- Hospices Civils de Lyon
Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis
Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis
This is a prospective, multicenter cohort observational; study to compare treatment outcomes in patients admitted to the hospital with Stevens-Johnsons Syndrome/Toxic Epidermolysis, aiming to assess the utility of medical…
- Conditions
- Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis, Drug Reaction
- Trial name
- NCT03585946
- Testing
- Site specific standard of care comparison
- Volunteers
- healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Gout Initiating Urate-loweringUrate-lowering Therapy, Gout Arthritis
HLA-B*58:01-Guided Therapy for Gout: Effectiveness, Safety, and Cost-Effectiveness
Severe cutaneous adverse reactions (SCARs), such as Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS), are rare but life-threatening complications that…
- Conditions
- Gout Initiating Urate-loweringUrate-lowering Therapy, Gout Arthritis, Gout and Hyperuricemia
- Trial name
- HLA-SCREEN (NCT07369622)
- Testing
- HLA-B*58:01 Genotyping, Allopurinol Tablet, Febuxostat
- Volunteers
- 228 people, healthy volunteers welcome
- Sponsor
- Haiphong University of Medicine and Pharmacy
Toxic Epidermal Necrolysis
Evaluation of the Efficacy and Safety of Methylprednisolone Combined With the JAK Inhibitors in the Treatment of Toxic Epidermal Necrolysis
To evaluate the efficacy and safety of methylprednisolone combined with the JAK inhibitor abxitinib and tofacitinib in the treatment of toxic epidermal necrolysis
- Trial name
- TEN (NCT06119490)
- Testing
- Abrocitinib, Tofacitinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peng Zhang
Toxic Epidermal Necrolysis, Stevens-Johnson Syndrome
Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis
To test the ability of palifermin (a recombinant human keratinocyte growth factor) to decrease mucocutaneous injury and to promote epithelial repair in Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome-Toxic Epidermal…
- Trial name
- NCT02037347
- Testing
- Palifermin
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Brett King
Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis
Study To Evaluate The Efficacy Of Tofacitinib In Patients With SJS/TEN
The goal of this study is to evaluate the effect of tofacitinib in patients with Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). The primary outcome of the study is the time to complete re-epithelialization.
- Trial name
- NCT06474078
- Testing
- Tofacitinib
- Where
- Taiwan
- Volunteers
- 20 people
- Sponsor
- Chang Gung Memorial Hospital
Epidermal Necrolysis, Lyell Syndrome
LYell SYndrome MEsenchymal Stromal Cells Treatment
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare severe cutaneous adverse reactions (SCARs) to drugs.
- Conditions
- Epidermal Necrolysis, Lyell Syndrome, Toxic Epidermal Necrolysis, Overlap Syndrome
- Trial name
- LYSYME (NCT04711200)
- Testing
- Adipose derived stromal cells intravenously injected
- Where
- France
- Volunteers
- 15 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Steven-Johnson Syndrome, Toxic Epidermal Necrolysis
Severe Cutaneous Adverse Reactions in Thailand
The multicenter registry of patients with severe cutaneous adverse reactions among tertiary medical institutes in Thailand to study clinical characteristics, etiologies, therapeutic outcomes, quality of life, and the values of in…
- Conditions
- Steven-Johnson Syndrome, Toxic Epidermal Necrolysis, Drug Reaction With Eosinophilia and Systemic Symptoms, Acute Generalized Exanthematous Pustulosis
- Trial name
- ThaiSCAR (NCT02574988)
- Where
- Thailand
- Volunteers
- 200 people
- Sponsor
- Chulalongkorn University
Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis (Lyell) Syndrome
Topical Infliximab in Autoimmune Eyes With Keratoprosthesis
The Boston Keratoprosthesis type I (KPro) is a prosthetic cornea used to treat several causes of corneal blindness. Some categories of patients, including those with auto-immune diseases such as Stevens-Johnson syndrome, toxic…
- Conditions
- Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis (Lyell) Syndrome, Mucous Membrane Pemphigoid
- Trial name
- NCT02126020
- Testing
- topical infliximab
- Where
- 2 sites in United States, Canada
- Sponsor
- James Chodosh, MD, MPH
Rare Diseases, Toxic Epidermal Necrolyses
Severe Bullous Drug Eruption and Filgrastim
Toxic epidermal necrolysis (TEN) including Stevens Johnson (SJS) and Lyell syndromes represent the most severe drug eruptions. It is an allergic disorder caused by cytotoxic T lymphocytes, specific of drugs, responsible for the…
- Trial name
- GNET (NCT04651439)
- Testing
- Filgrastim
- Where
- 3 sites in France
- Volunteers
- 42 people
- Sponsor
- Hospices Civils de Lyon
Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis
Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids.
Patients diagnosed with Stevens-Johnson syndrome and Toxic Epidermal Necrolysis were confirmed based on the investigators national diagnostic criteria.
- Trial name
- NCT01696500
- Testing
- Intravenous immunoglobulin
- Where
- Japan
- Volunteers
- 10 people
- Sponsor
- Nihon Pharmaceutical Co., Ltd
Cicatrizing Conjunctivitis, Stevens-Johnson Syndrome Toxic Epidermal Necrolysis Spectrum
Minor Salivary Gland Transplantation for Cicatrizing Conjunctivitis
This is a prospective study that aimed to observe the therapeutic effects of minor salivary gland transplantation for cicatrizing conjunctivitis patients.
- Conditions
- Cicatrizing Conjunctivitis, Stevens-Johnson Syndrome Toxic Epidermal Necrolysis Spectrum, Sjogren Syndrome, Mucous Membrane Pemphigoid
- Trial name
- NCT03839069
- Testing
- minor salivary gland transplantation
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- National Taiwan University Hospital
Stevens-Johnson Syndrome, Toxic Epidermal Necrolyses
NATIENS: Optimal Management and Mechanisms of SJS/TEN
The North American Therapeutics in Epidermal Necrolysis Syndrome (NATIENS) study is a multicenter double-blind randomized controlled assessment of two arms - one of systemic immunomodulatory therapy (etanercept) and one of…
- Trial name
- NATIENS (NCT02987257)
- Testing
- Harmonized supportive care, Etanercept 50 mg sc day 1 and day 4
- Where
- 14 sites in United States
- Volunteers
- 2 people
- Sponsor
- Vanderbilt University Medical Center
Stevens - Johnson Syndrome
G-CSF in the Treatment of Toxic Epidermal Necrolysis
NeupoNET aims to evaluate interest of G-CSF in the treatment of Toxic Epidermal necrolysis. This is a prospective randomized controlled trial.
- Trial name
- NeupoNET (NCT02739295)
- Testing
- recombinant granulocyte - colony stimulating factor, NaCl 0.9%
- Where
- 2 sites in Belgium
- Volunteers
- 10 people
- Sponsor
- University of Liege
Stevens-Johnson Syndrome, Toxic Epidermal Necrolyses
Meibomian Gland Probing in the Sub-Acute Phase of Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis
The investigators' aim is to study the effects of mechanical expression of meibomian glands on eyelid disease, ocular surface health in the subacute phase of SJS/TEN.
- Conditions
- Stevens-Johnson Syndrome, Toxic Epidermal Necrolyses, Ocular Surface Disease, Meibomitis
- Trial name
- NCT05145959
- Testing
- Maskin Probe
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Massachusetts Eye and Ear Infirmary
Toxic Epidermal Necrolysis
Study of a Potential New Treatment for Patients With Toxic Epidermal Necrolysis (TEN)
To determine whether treatment of patients who have toxic epidermal necrolysis with a drug called remicaide increases the number of patients who are alive 30 days laters.
- Trial name
- NCT00372723
- Testing
- Remicaide (infliximab)
- Sponsor
- Loyola University
Immune Checkpoint Inhibitor-Induced Dermatitis, Stevens-Johnson Syndrome, Drug-Induced
SJS/TEN or Other Cutaneous Adverse Eevents Induced by Immune Checkpoint Inhibitors (ICIs) vs. Non-ICIs
Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) is a severe adverse drug reaction, characterized by extensive skin detachment.
- Conditions
- Immune Checkpoint Inhibitor-Induced Dermatitis, Stevens-Johnson Syndrome, Drug-Induced, Toxic Epidermal Necrolysis Due to Drug
- Trial name
- NCT06522048
- Testing
- Observational studies do not require intervention
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Chao Ji
Inflammatory Response, Multi Organ Failure
Association of Cytokines With the Development of Complications in Burn and Toxic Epidermal Necrolysis (TENS) Patients
This study will involve blood draws to test for specific cytokines. The study goal is to gain a better understanding of the role of inflammatory response in the development of specific complications in burn and TENS patients.
- Conditions
- Inflammatory Response, Multi Organ Failure, Nosocomial Infection, Deep Vein Thrombosis
- Trial name
- NCT04252651
- Testing
- Blood Draw
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Joseph M. Still Research Foundation, Inc.
Stevens-Johnson Syndrome, Corneal Blindness
Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis (SJS/TENS)
The proposed study is intended to test the idea, based upon current knowledge of the biology and physiology of corneal ulceration in SJS/TENS patients who receive a keratoprosthesis, and on the known effects of infliximab on…
- Trial name
- NCT01256489
- Testing
- Infliximab
- Where
- United States
- Sponsor
- Massachusetts Eye and Ear Infirmary